查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1790404

美国抗体药物复合体市场规模、份额和趋势分析报告：按应用、技术、产品、目标和细分市场预测，2025 年至 2030 年

U.S. Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer), By Technology, By Product, By Target, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国抗体药物复合体市场摘要

预计 2024 年美国抗体药物复合体市场价值将达到 71.5 亿美元，2025 年至 2030 年期间的复合年增长率为 4.9%，到 2030 年将达到 106 亿美元。这是由癌症发生率的上升和对低毒性有效药物的需求不断增长所推动的。

此外，製药和生技公司正大力投资抗体药物复合体(ADC) 的研发，推动市场成长。美国癌症患者数量的增加极大地推动了对 ADC 等标靶治疗的需求。据美国癌症协会称，到 2024 年，美国将诊断出 200 多万例新癌症病例。由于人口老化、生活方式的改变和诊断能力的提高等各种因素，癌症患者的数量正在增加。 ADC 提供了一种高度针对性的方法，将细胞毒药物直接输送到癌细胞并最大限度地减少对健康组织的损害。这种精确性使得 ADC 比传统化疗更受欢迎，特别是对于难治性癌症。

资金筹措的增加正在加速ADC的开发，使其适应症范围超越肿瘤学。例如，2025年3月，专注于研发用于癌症治疗的多负载ADC的生物技术公司Kario Therapeutics在获得由Frazier Life Sciences主导的1.87亿美元A轮资金筹措后宣布推出。 Kario计划利用这笔资金推进其HER2靶向双负载ADC的临床验证。

抗体製造、连接体稳定性和细胞毒性有效载荷领域的不断创新，正在推动高效、更安全的 ADC 的开发。 2024 年 9 月，默克推出了 Möbius ADC 反应器，这是一款一次性反应器，旨在生产能够精准靶向并清除癌细胞，同时不损害健康组织的 ADC。

併购低迷，知名製药公司专注于收购在ADC技术方面拥有专长的公司，以增强其肿瘤产品组合。例如，强生服务公司于2024年3月收购了Ambrx Biopharma, Inc.，该公司拥有专有的合成生物学技术平台，用于开发和设计下一代ADC，预计这些ADC将带来差异化的固体癌治疗方案，从而改善患者的生活。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国抗体药物复合体市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关市场展望
  • 产业价值链分析
  • 法律规范
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 产业挑战
    • 行业机会
  • 产业分析工具
    • 波特五力分析
    • 宏观环境分析

第四章：美国抗体药物复合体市场：应用估计与趋势分析

  • 细分仪表板
  • 美国抗体药物复合体市场：应用变化分析和市场占有率（2024 年和 2030 年）
  • 血癌
    • 白血病
    • 淋巴瘤
    • 多发性骨髓瘤
  • 乳癌
  • 尿路上皮癌和膀胱癌
  • 其他癌症

第五章美国抗体药物复合体市场：产品估计与趋势分析

  • 细分仪表板
  • 美国抗体药物复合体市场：2024 年和 2030 年产品变化分析和市场占有率
  • 门头
  • 恩格尔图
  • ADCETRIS
  • 帕德切夫
  • 特罗德尔维
  • 波利维
  • 其他的

第六章：美国抗体药物复合体市场：目标估计与趋势分析

  • 细分仪表板
  • 美国抗体药物复合体市场：2024 年及 2030 年标靶变异分析及市场占有率
  • HER2
  • CD22
  • CD30
  • 其他的

第七章：美国抗体药物复合体市场：技术评估与趋势分析

  • 细分仪表板
  • 美国抗体药物复合体市场：2024 年和 2030 年技术变革分析和市场占有率
  • 类型
    • 可裂解接头
    • 不可切割的连接子
    • 无连结
  • 连结器技术类型
    • VC
    • Sulfo-SPDB
    • VA
    • Hydrazone
    • 其他的
  • 有效载荷技术
    • MMAE
    • MMAF
    • DM4
    • 喜树碱
    • 其他的

第八章美国抗体药物复合体市场－竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图
  • Position Analysis, 2024
  • 战略地图
    • 扩张
    • 合併与收购
    • 伙伴关係和合作
    • 新产品发布
    • 研究与开发
  • 公司简介
    • Seagen, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Gilead Sciences, Inc.
    • Daiichi Sankyo Company Ltd.
    • GlaxoSmithKline Plc
    • Astellas Pharma, Inc.
    • ADC Therapeutics SA
Product Code: GVR-4-68040-670-8

U.S. Antibody Drug Conjugates Market Summary

The U.S. antibody drug conjugates market size was valued at USD 7.15 billion in 2024 and is projected to reach USD 10.60 billion by 2030, growing at a CAGR of 4.9% from 2025 to 2030. This can be attributed to the increasing incidence of cancer cases and increased demand for low-toxicity & effective drugs.

Also, pharmaceutical and biotech companies are investing heavily in researching and developing antibody drug conjugates (ADCs), propelling market growth. The growing number of cancer cases in the U.S. significantly fuels demand for targeted therapies like ADCs. According to the American Cancer Society Inc., in 2024, over 2 million new cancer cases were detected in the U.S. The number of cancer cases is rising due to various factors such as aging populations, lifestyle changes, and improved diagnostic capabilities. ADCs offer a highly focused approach that delivers cytotoxic drugs straight to cancer cells, reducing damage to healthy tissues. This accuracy makes ADCs preferred to traditional chemotherapy, especially for challenging cancers.

The rising funding is accelerating the development of ADCs across a wider range of indications beyond oncology. For instance, in March 2025, Callio Therapeutics, a biotechnology firm dedicated to multi-payload ADCs aimed at cancer treatment, declared its launch after securing USD 187 million in Series A funding led by Frazier Life Sciences. Callio intends to use the funds to progress clinical proof-of-concept for its HER2-targeted dual-payload ADC.

The rising technological innovations in antibody manufacturing, linker stability, and cytotoxic payloads have led to the development of effective and safer ADCs. In September 2024, Merck launched the Mobius ADC Reactor, a single-use reactor designed to manufacture ADCs that precisely target and eliminate tumor cells while leaving healthy tissue unharmed.

Mergers and acquisitions (M&A) are moderate, with prominent pharmaceutical companies focusing on acquiring companies with expertise in ADC technologies to improve their oncology portfolios. For instance, in March 2024, Johnson & Johnson Services, Inc. acquired Ambrx Biopharma, Inc. It has a proprietary synthetic biology technology platform to develop and design next-generation ADC. This is expected to deliver differentiated solid tumor treatment to improve the lives of patients'.

U.S. Antibody Drug Conjugates Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. antibody drug conjugates market report based on application, product, target, and technology:

  • Application (Revenue, USD Million, 2018 - 2030)
  • Blood Cancer
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
  • Breast Cancer
  • Urothelial Cancer & Bladder Cancer
  • Other Cancer
  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others
  • Target Outlook (Revenue, USD Million, 2018 - 2030)
  • HER2
  • CD22
  • CD30
  • Others
  • Technology Outlook (Revenue, USD Million, 2018 - 2030)
  • Type
    • Cleavable Linker
    • Non-cleavable Linker
    • Linkerless
  • Linker Technology Type
    • VC
    • Sulfo-SPDB
    • VA
    • Hydrazone
    • Others
  • Payload Technology
    • MMAE
    • MMAF
    • DM4
    • Camptothecin
    • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources & Third-Party Perspectives
    • 1.3.4. Primary Research
  • 1.4. Information Analysis
    • 1.4.1. Data Analysis Models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Antibody Drug Conjugates Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related Market Outlook
  • 3.2. Industry Value Chain Analysis
  • 3.3. Regulatory Framework
  • 3.4. Market Dynamics
    • 3.4.1. Market Driver Analysis
    • 3.4.2. Market Restraint Analysis
    • 3.4.3. Industry Challenges
    • 3.4.4. Industry Opportunities
  • 3.5. Industry Analysis Tools
    • 3.5.1. Porter's Five Forces Analysis
    • 3.5.2. Macro-environmental Analysis

Chapter 4. U.S. Antibody Drug Conjugates Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Antibody Drug Conjugates Market: Application Movement Analysis & Market Share, 2024 & 2030
  • 4.3. Blood Cancer
    • 4.3.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Leukemia
      • 4.3.2.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Lymphoma
      • 4.3.3.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Multiple Myeloma
      • 4.3.4.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Urothelial Cancer & Bladder Cancer
    • 4.5.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Other Cancer
    • 4.6.1. Urothelial Cancer & Bladder Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Antibody Drug Conjugates Market: Product Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Antibody Drug Conjugates Market: Product Movement Analysis & Market Share, 2024 & 2030
  • 5.3. Kadcyla
    • 5.3.1. Kadcyla Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Enhertu
    • 5.4.1. Enhertu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Adcetris
    • 5.5.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Padcev
    • 5.6.1. Padcev Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Trodelvy
    • 5.7.1. Trodelvy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Polivy
    • 5.8.1. Polivy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Antibody Drug Conjugates Market: Target Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Antibody Drug Conjugates Market: Target Movement Analysis & Market Share, 2024 & 2030
  • 6.3. HER2
    • 6.3.1. HER2 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. CD22
    • 6.4.1. CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. CD30
    • 6.5.1. CD30 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Antibody Drug Conjugates Market: Technology Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Antibody Drug Conjugates Market: Technology Movement Analysis & Market Share, 2024 & 2030
  • 7.3. Type
    • 7.3.1. Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. Cleavable Linker
      • 7.3.2.1. Cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Non-cleavable Linker
      • 7.3.3.1. Non-cleavable Linker Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Linkerless
      • 7.3.4.1. Linkerless Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Linker Technology Type
    • 7.4.1. Linker Technology Type Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. VC
      • 7.4.2.1. VC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Sulfo-SPDB
      • 7.4.3.1. Sulfo-SPDB Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. VA
      • 7.4.4.1. VA Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Hydrazone
      • 7.4.5.1. Hydrazone Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Others
      • 7.4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Payload Technology
    • 7.5.1. Payload Technology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. MMAE
      • 7.5.2.1. MMAE Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. MMAF
      • 7.5.3.1. MMAF Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. DM4
      • 7.5.4.1. DM4 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Camptothecin
      • 7.5.5.1. Camptothecin Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Others
      • 7.5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Antibody Drug Conjugates Market - Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map
  • 8.4. Position Analysis, 2024
  • 8.5. Strategy Mapping
    • 8.5.1. Expansion
    • 8.5.2. Mergers & Acquisition
    • 8.5.3. Partnerships & Collaborations
    • 8.5.4. New Product Launches
    • 8.5.5. Research and Development
  • 8.6. Company Profiles
    • 8.6.1. Seagen, Inc.
      • 8.6.1.1. Participant's overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Product benchmarking
      • 8.6.1.4. Recent developments
    • 8.6.2. Takeda Pharmaceutical Company Ltd.
      • 8.6.2.1. Participant's overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Product benchmarking
      • 8.6.2.4. Recent developments
    • 8.6.3. AstraZeneca
      • 8.6.3.1. Participant's overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Product benchmarking
      • 8.6.3.4. Recent developments
    • 8.6.4. F. Hoffmann-La Roche Ltd.
      • 8.6.4.1. Participant's overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Product benchmarking
      • 8.6.4.4. Recent developments
    • 8.6.5. Pfizer, Inc.
      • 8.6.5.1. Participant's overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Product benchmarking
      • 8.6.5.4. Recent developments
    • 8.6.6. Gilead Sciences, Inc.
      • 8.6.6.1. Participant's overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Product benchmarking
      • 8.6.6.4. Recent developments
    • 8.6.7. Daiichi Sankyo Company Ltd.
      • 8.6.7.1. Participant's overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Product benchmarking
      • 8.6.7.4. Recent developments
    • 8.6.8. GlaxoSmithKline Plc
      • 8.6.8.1. Participant's overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Product benchmarking
      • 8.6.8.4. Recent developments
    • 8.6.9. Astellas Pharma, Inc.
      • 8.6.9.1. Participant's overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Product benchmarking
      • 8.6.9.4. Recent developments
    • 8.6.10. ADC Therapeutics SA
      • 8.6.10.1. Participant's overview
      • 8.6.10.2. Financial performance
      • 8.6.10.3. Product benchmarking
      • 8.6.10.4. Recent developments

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. antibody drug conjugates market 2018 - 2030 (USD Million)
  • Table 3 U.S. antibody drug conjugates market estimates and forecasts by application, 2018 - 2030 (USD Million)
  • Table 4 U.S. antibody drug conjugates market estimates and forecasts by product, 2018 - 2030 (USD Million)
  • Table 5 U.S. antibody drug conjugates market estimates and forecasts by target, 2018 - 2030 (USD Million)
  • Table 6 U.S. antibody drug conjugates market estimates and forecasts by technology, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Data Triangulation Techniques
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 QFD Modeling for Market Share Assessment
  • Fig. 6 Information Procurement
  • Fig. 7 Market Formulation and Validation
  • Fig. 8 Data Validating & Publishing
  • Fig. 9 Market Segmentation & Scope
  • Fig. 10 U.S. Antibody Drug Conjugates Market Snapshot
  • Fig. 11 Segment Snapshot (1/2)
  • Fig. 12 Segment Snapshot (1/2)
  • Fig. 13 Competitive Landscape Snapshot
  • Fig. 14 Parent market outlook
  • Fig. 15 U.S. Antibody Drug Conjugates Market Value, 2024 (USD Million)
  • Fig. 16 U.S. Antibody Drug Conjugates Market - Value Chain Analysis
  • Fig. 17 U.S. Antibody Drug Conjugates Market - Market Dynamics
  • Fig. 18 U.S. Antibody Drug Conjugates Market - PORTER's Analysis
  • Fig. 19 U.S. Antibody Drug Conjugates Market - PESTEL Analysis
  • Fig. 20 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
  • Fig. 21 U.S. Antibody Drug Conjugates Market Share, by Application, 2024 & 2030
  • Fig. 22 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Application: Key Takeaways
  • Fig. 23 Blood Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Leukemia Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Lymphoma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Multiple Myeloma Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Breast Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Urothelial Cancer & Bladder Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Other Cancer Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Product: Key Takeaways
  • Fig. 31 U.S. Antibody Drug Conjugates Market Share, by Product, 2024 & 2030
  • Fig. 32 Kadcyla Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Enhertu Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Adcetris Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Padcev Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Trodelvy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Polivy Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Target: Key Takeaways
  • Fig. 40 U.S. Antibody Drug Conjugates Market Share, by Target, 2024 & 2030
  • Fig. 41 HER2 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 CD22 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 CD30 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Antibody Drug Conjugates Market Estimates & Forecasts, by Technology: Key Takeaways
  • Fig. 46 U.S. Antibody Drug Conjugates Market Share, by Technology, 2024 & 2030
  • Fig. 47 Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Non-cleavable Linker Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Linkerless Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Linker Technology Type Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 VC Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Sulfo-SPDB Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 VA Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Hydrazone Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Payload Technology Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 MMAE Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 MMAF Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 DM4 Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Camptothecin Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Others Market Estimates & Forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key Company Categorization
  • Fig. 64 Company Market Positioning
  • Fig. 65 Strategy Mapping